LAVIPHARM S.A. NA EO 1 (BXA0) — Cash Flow Reinvestment Rate
LAVIPHARM S.A. NA EO 1 (BXA0) has a Cash Flow Reinvestment Rate of 2.08x as of December 2024, reinvesting €9.64 Million (capex €9.64 Million ) from operating cash flow of €4.64 Million. See LAVIPHARM S.A. NA EO 1 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
LAVIPHARM S.A. NA EO 1 Cash Flow Reinvestment Rate (2021–2024)
Historical reinvestment intensity for LAVIPHARM S.A. NA EO 1 across 4 annual periods. For the full cash flow conversion analysis, see LAVIPHARM S.A. NA EO 1 cash flow conversion.
Annual Cash Flow Reinvestment Rate for LAVIPHARM S.A. NA EO 1 (2021–2024)
Year-by-year capital reinvestment analysis for LAVIPHARM S.A. NA EO 1. See LAVIPHARM S.A. NA EO 1 (BXA0) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.08x | €9.64 Million | €4.64 Million | €9.64 Million | ▼ -85.4% |
| 2023 | 14.26x | €4.05 Million | €284.00K | €4.05 Million | ▲ +33.9% |
| 2022 | 10.64x | €35.62 Million | €3.35 Million | €35.62 Million | ▲ +2181.6% |
| 2021 | 0.47x | €1.92 Million | €4.11 Million | €1.92 Million | — |